A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

被引:0
作者
Tânia Santiago
Mariana Galante Santiago
João Rovisco
Cátia Duarte
Armando Malcata
José António Pereira da Silva
机构
[1] Hospitais da Universidade de Coimbra,Clínica Universitária de Reumatologia (CURe)
来源
Clinical Rheumatology | 2013年 / 32卷
关键词
Ankylosing spondylitis; Anti-TNF-α; Anti-TNF-α-induced lupus; Drug-induced lupus; Infliximab;
D O I
暂无
中图分类号
学科分类号
摘要
Anti-TNF-α therapies are the latest class of medications found to be associated with drug-induced lupus, a distinctive entity known as anti-TNF-α-induced lupus (ATIL) (Williams et al., Rheumatology (Oxford) 48:716–20, 2009; De Rycke et al., Lupus 14:931–7, 2005; De Bandt et al., Clin Rheumatol 22:56–61, 2003). With the widespread use of these agents, it is likely that the incidence of ATIL will increase. The onset of ATIL in patients with rheumatoid arthritis and Crohn's disease has been described, but the literature regarding the occurrence of this entity in patients with ankylosing spondylitis (AS) is scarce (De Bandt et al., Clin Rheumatol 22:56–61, 2003; Ramos-Casals et al., Autoimmun Rev 9:188–93, 2010; Perez-Garcia et al., Rheumatology 45:114–116, 2006). To our knowledge, few reports of switching anti-TNF-α therapy after ATIL in AS have been reported (Akgül et al., Rheumatol Int, 2012). Therefore, it is not clear whether the development of ATIL should prohibit switch to another therapy, since patients may respond to another anti-TNF-α agent (Akgül et al., Rheumatol Int, 2012; Bodur et al., Rheumatol Int 29:451–454, 2009; Mounach et al., Clin Exp Rheumatol 26:1116–8, 2008; Williams and Cohen, Int J Dermatol 50:619–625, 2011; Ye et al., J Rheumatol 38:1216, 2011; Wetter and Davis, Mayo Clin Proc 84:979–984, 2009; Cush, Clin Exp Rheumatol 22:S141–147, 2004; Kocharla and Mongey, Lupus 18:169–7, 2009). A lack of published experience of successful anti-TNF-α switching is a cause of concern for rheumatologists faced with this challenging clinical scenario. We report the case of a 69-year-old woman with AS who developed infliximab-induced lupus, which did not recur despite the subsequent institution of etanercept. The authors review and discuss ATIL and the possible implications for subsequent treatment with alternative anti-TNF-α agents.
引用
收藏
页码:1819 / 1822
页数:3
相关论文
共 47 条
[1]  
Williams EL(2009)Anti-TNF-induced lupus Rheumatology (Oxford) 48 716-720
[2]  
Gadola S(2005)The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications Lupus 14 931-937
[3]  
Edwards CJ(2003)Anti-TNF alpha-induced systemic lupus erythematosus Clin Rheumatol 22 56-61
[4]  
De Rycke L(2010)Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9 188-193
[5]  
Baeten D(2006)Drug-induced systemic lupus erythematous in ankylosing spondylitis associated in infliximab Rheumatology 45 114-116
[6]  
Kruithof E(2012)Patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept Rheumatol Int 29 451-454
[7]  
Van den Bosch F(2009)Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis Rheumatol Int 26 1116-1118
[8]  
Veys EM(2008)Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab Clin Exp Rheumatol 50 619-625
[9]  
De Keyser F(2011)TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists Int J Dermatol 38 1216-984
[10]  
De Bandt M(2011)Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent J Rheumatol 84 979-S147